Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of JNJ-55308942 in Healthy Subjects
NCT03151486Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zanvipixant in bipolar disorder (BD) (11 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events up to 6 Weeks, Maximum Observed Plasma Concentration (Cmax) of JNJ-55308942 (SAD) and 7 more. Started May 2017; status: completed.
02
Drugs
zanvipixant
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03151486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151486.